Lead Sponsor

Centre Francois Baclesse

Age

18 - No limit years

Sex

FEMALE

Healthy Volunteers

No

•Women aged over 18
•Invasive breast carcinoma confirmed histologically
•Non-metastatic cancer
•Surgery of the primary tumor performed (mastectomy or lumpectomy) and associated with an audit axillary (sentinel node and / or axillary dissection)
•Patient should receive their last course of adjuvant chemotherapy (3 FEC and 3 Taxotere)
•Patients not receiving the third course of Taxotere because of toxicities may be included in the fifth course of chemotherapy is the second of Taxotere
•For the group Herceptin ®: HER2 overexpression without contraindication to treatment administration
•For the control group: no indication for Herceptin ®
•Radiation therapy and / or adjuvant hormonal therapy allowed
•Free and informed consent signed

•Women under 18 or over 60 years
•Histology other than adenocarcinoma
•Metastatic Breast Cancer
•Chemotherapy neoadjuvant
•Surgery of the primary tumor unrealized
•Lack of adjuvant chemotherapy with Taxotere 3 FEC and 3
•Patients with a history of malignancy within 5 years, outside of a basal cell cancer or cancer of the cervix treated and cured
•Patient under guardianship or unable to give informed consent,
•Pregnant or lactating
•Patient unable to undergo a medical for geographical, social or psychopathological

Related studies

NCT06347068 · Breast Cancer, Relapse, and more

NCT06500481 · Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, and more

NCT07655934 · Breast Cancer

NCT07436078 · Female Breast Cancer, Prostate Cancer, and more

NCT06188520 · ER+ HER2- Advanced Breast Cancer, High-grade Serous Ovarian Cancer (HGSOC)

Experience of the Patient Treated With Trastuzumab (Herceptin ®) as Adjuvant for Breast Cancer